| Identification | Back Directory | [Name]
lankacidins | [CAS]
23623-31-6 | [Synonyms]
Bundlin A
Lankacidin
NSC 145118
lankacidins
Lankacidin C
Antibiotic T-2636C
N-[(1S,2R,3E,5E,7S,9E,11E,13S,15R,19R)-7,13-Dihydroxy-1,4,10,19-tetramethyl-17,18-dioxo-16-oxabicyclo[13.2.2]nonadeca-3,5,9,11-tetraen-2-yl]-2-oxopropanamide
Propanamide, N-[(1S,2R,3E,5E,7S,9E,11E,13S,15R,19R)-7,13-dihydroxy-1,4,10,19-tetramethyl-17,18-dioxo-16-oxabicyclo[13.2.2]nonadeca-3,5,9,11-tetraen-2-yl]-2-oxo-
N-[[1S,2R,3E,5E,7S,9E,11E,13S,15R,19R,(-)]-7,13-Dihydroxy-1,4,10,19-tetramethyl-17,18-dioxo-16-oxabicyclo[13.2.2]nonadeca-3,5,9,11-tetraen-2-yl]-2-oxopropanamide | [Molecular Formula]
C25H33NO7 | [MDL Number]
MFCD01939935 | [MOL File]
23623-31-6.mol | [Molecular Weight]
459.53 |
| Hazard Information | Back Directory | [Uses]
Lankacidin C is an inhibitor of protein synthesis in vitro. Lankacidin C inhibits the activity of L1210 leukemia, B16 melanoma and 6C3 HED/OG lymphosarcoma cell lines. Lankacidin C has antibacterial activity and antitumor activity[1][2]. | [Definition]
ChEBI: Lankacidin C is an organic molecular entity. | [in vivo]
Lankacidin C (75-1000 mg/kg; i.p.; once daily for 5 d) prolongs the mean survival time of (C57BL/6×DBA/2) F1 (BDF1) mice with dose-dependent manner. Lankacidin C (1000 mg/kg) significantly inhibits the growth of B-16 melanoma in C57BL/6 mice implanted B-16 melanoma[2].
Lankacidin C (300 mg/kg; i.p.; once daily for 6 d) inhibits the activity of L-1210 cells that resistance to 6-Mercaptopurine (HY-13677) or Cytosine Arabinoside (HY-13605) in BDF1 mice bearing L-1210/6-Mercaptopurine or L-1210/Cytosine Arabinoside[2].
Lankacidin C (10-100 mg/kg; i.p.; once daily for 5 d) significantly prolongs the mean survival time of C3H/He mice bearing 6C3HED/OG or 6C3HED/RG lymphosarcoma[2].
Lankacidin C (500 mg/kg; i.p.; once daily for 3 or 4 d) suppresses the production of antibody against sheep erythrocytes in ICR mice when administered before or after antigenic stimulation[2].
| Animal Model: | C57BL/6, C3H/He, ICR and (C57BL/6×DBA/2) F1 (BDF1) mice[2]. | | Dosage: | 10, 20, 25, 30, 40, 50, 100, 150, 250, 300, 500, 600 or 1000 mg/kg | | Administration: | Intraperitoneal injection; once daily for 3, 4, 5 or 6 days | | Result: | Inhibited the growth of L1210 leukemia, B16 melanoma and 6C3 HED/OG or 6C3 HED/RG lymphosarcoma cells. |
| [References]
[1] Cai L, et al. Modular Approaches to Lankacidin Antibiotics. J Am Chem Soc. 2020 Sep 2;142(35):15116-15126. DOI:10.1021/jacs.0c06648
[2] Ootsu K, et al. Effects of Lankacidin group (T2636) antibiotics on the tumor growth and immune response against sheep erythrocytes in mice. Gan. 1973 Oct;64(5):481-92. PMID:4801122 |
|
|